Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Abzena announced the completion of the facility remodeling for its new antibody-drug conjugate GMP manufacturing suite at its Bristol, Pennsylvania site.
read more
Abzena announced the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory ...
read more
Thursday, October 31, 2024
Abzena announced a significant expansion in their quality control (QC) testing capabilities at their San Diego, CA biologics development and cGMP manufacturing site.
read more
Tuesday, February 13, 2024
Abzena has announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs...
read more
These ex-vivo platform approaches allow efficacy and safety studies against clinically characterized on and off-target tissues.
read more
Wednesday, October 27, 2021
Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to commercial for large molecules and bioconjugates, announced it has promoted Dr. Louise Duffy as Chief Technical Officer.
read more
Monday, December 20, 2021
Abzena, the leading Partner Research Organization (PRO) for outsourced solutions integrating gene to commercial for large molecules and bioconjugates, announced it has promoted Troy Wright to Senior Vice President and Global Head of Quality. ...
read more
Abzena has announced a $10M investment of growth capital from Biospring Partners, a New York based investment firm.
read more
Monday, February 08, 2021
Immunome announced that Abzena was selected as Immunome’s partner research organization for IMM-BCP-01, an investigational therapeutic antibody cocktail for the treatment of COVID-19 being developed to target multiple SARS-CoV-2 antigens.
read more
Abzena Selects IPS for Turnkey Delivery of Their New CGMP Facility in North Carolina
IPS-Integrated Project Services, LLC, a provider of engineering, procurement, construction management, and validation (EPCMV) services, announces its support to ...
read more
Vectalys and FlashCell have merged to create Flash Therapeutics, a new privately held gene therapy company developing gene and cell therapeutics.
read more
Waverley Pharma announced its wholly-owned Irish Subsidiary has submitted a Marketing Authorization application through the European Union's De-Centralized Procedure for an anti-cancer generic drug.
read more
Abzena has entered into a master service agreement with NYU Langone Health.
read more
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for their Phase 1 clinical trial of AGX101, a first-in-class TM4SF1-directed Antibody-Drug Conjugate (ADC)...
read more
Wednesday, January 17, 2024
Abzena has introduced the AbZelect™ and AbZelectPRO™ platforms for accelerating the generation of production cell lines used in the manufacturing of antibodies and recombinant proteins.
read more